Skip to content. | Skip to navigation

Garvan Institute

Sections
 

Grey

 

Group Leader
Associate Professor Shane T Grey

 

Our laboratory is interested in gene therapy and autoimmunity. That is, we investigate the immune system’s attack on the body’s tissues as it occurs during the rejection of organ grafts and in autoimmune disorders like type I diabetes where the insulin-producing beta cells are destroyed. Approaches include examining factors that regulate the immune attack on our own cells and investigating the molecular changes that occur in the tissue being attacked in the hope of, one day, being able to genetically engineer tissues that could withstand the assault. This strategy would alleviate the need for the toxic immunosuppressive drugs currently required to promote successful organ transplantation and, in the case of type 1 diabetes, enable creation of a ‘death-defying’ beta cell as a novel cure.

 

Staff

 

Stacey WaltersResearch Assistant
Stacey Walters
Bernice TanResearch Assistant
Bernice Tan
Nathan ZammitPhD Student
Nathan Zammit
Jeanette VillanuevaPhD Student
Jeanette Villanueva



Elisabeth MallePhD Student
Elisabeth Malle


 

 

 

 

 

 

News

 

Transplantation society awards two Garvan immunologists

05 Jul 2011
Two PhD students from the Grey lab were distinguished by The Transplantation Society of Australia and New Zealand (TSANZ) at its annual conference last week - Jeanette Villanueva and Nathan Zammit. Jeanette won the prestigious Kidney Health Australia Award for the best overall laboratory-based abstract and presentation. She also won a Young Investigator Award, as did Nathan Zammit.
 
 

Shane Grey wins award for diabetes research

07 Sep 2010
Garvan immunologist Dr Shane Grey has won the prestigious 2010 Juvenile Diabetes Research Foundation / Macquarie Group Foundation Diabetes Research Innovation Award for an Early Career Researcher.
 
 

Potential preventative therapy for Type 1 diabetes

MEDIA RELEASE: 29 Apr 2009
Immunology researchers at Garvan believe they may have found a preventative therapy for Type 1 diabetes, by making the body's killer immune cells tolerate the insulin-producing cells they would normally attack and destroy, prior to disease onset.
 
 

Personal tools